Steven E McKenzie1, Bruce S Sachais. 1. aDepartment of Medicine, Cardeza Foundation for Hematological Research, Thomas Jefferson University bDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Abstract
PURPOSE OF REVIEW: To review the recent developments in understanding the pathophysiology of heparin-induced thrombocytopenia (HIT) and in applying this knowledge to the treatment of patients with suspected and proven HIT. RECENT FINDINGS: HIT pathophysiology is dynamic and complex. HIT pathophysiology is initiated by four essential components--heparin (Hep), platelet factor 4 (PF4), IgG antibodies against the Hep-PF4 complex, and platelet FcγRIIa. HIT is propagated by activated platelets, monocytes, endothelial cells, and coagulation proteins. Insights into the unique HIT antibody response continue to emerge, but without consensus as to the relative roles of B cells, T cells, and antigen-presenting cells. Platelet activation via FcγRIIa, the sine qua non of HIT, has become much better appreciated. Therapy remains challenging for several reasons. Suspected HIT is more frequent than proven HIT, because of the widespread use of Hep and the inadequacies of current diagnostic tests and scoring systems. In proven HIT, approved treatments reduce but do not eliminate thrombosis, and have substantial bleeding risk. Rational novel therapeutic strategies, directed at the initiating steps in HIT pathophysiology and with potential combinations staged over time, are in various phases of development. SUMMARY: Progress continues in understanding the breadth of molecular and cellular players in HIT. Translation to improved diagnosis and treatment is needed.
PURPOSE OF REVIEW: To review the recent developments in understanding the pathophysiology of heparin-induced thrombocytopenia (HIT) and in applying this knowledge to the treatment of patients with suspected and proven HIT. RECENT FINDINGS:HIT pathophysiology is dynamic and complex. HIT pathophysiology is initiated by four essential components--heparin (Hep), platelet factor 4 (PF4), IgG antibodies against the Hep-PF4 complex, and platelet FcγRIIa. HIT is propagated by activated platelets, monocytes, endothelial cells, and coagulation proteins. Insights into the unique HIT antibody response continue to emerge, but without consensus as to the relative roles of B cells, T cells, and antigen-presenting cells. Platelet activation via FcγRIIa, the sine qua non of HIT, has become much better appreciated. Therapy remains challenging for several reasons. Suspected HIT is more frequent than proven HIT, because of the widespread use of Hep and the inadequacies of current diagnostic tests and scoring systems. In proven HIT, approved treatments reduce but do not eliminate thrombosis, and have substantial bleeding risk. Rational novel therapeutic strategies, directed at the initiating steps in HIT pathophysiology and with potential combinations staged over time, are in various phases of development. SUMMARY: Progress continues in understanding the breadth of molecular and cellular players in HIT. Translation to improved diagnosis and treatment is needed.
Authors: Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Tamam Bakchoul; Heike Zöllner; Jean Amiral; Simon Panzer; Sixten Selleng; Thomas Kohlmann; Sven Brandt; Mihaela Delcea; Theodore E Warkentin; Ulrich J Sachs; Andreas Greinacher Journal: Blood Date: 2013-01-16 Impact factor: 22.113
Authors: Rustem I Litvinov; Serge V Yarovoi; Lubica Rauova; Valeri Barsegov; Bruce S Sachais; Ann H Rux; Jillian L Hinds; Gowthami M Arepally; Douglas B Cines; John W Weisel Journal: J Biol Chem Date: 2013-10-04 Impact factor: 5.157
Authors: Karina Althaus; Gregor Hron; Ulrike Strobel; Rosanna Abbate; Angela Rogolino; Simon Davidson; Andreas Greinacher; Tamam Bakchoul Journal: Thromb Res Date: 2013-01-23 Impact factor: 3.944
Authors: L Ziporen; Z Q Li; K S Park; P Sabnekar; W Y Liu; G Arepally; Y Shoenfeld; T Kieber-Emmons; D B Cines; M Poncz Journal: Blood Date: 1998-11-01 Impact factor: 22.113
Authors: Lubica Rauova; Mortimer Poncz; Steven E McKenzie; Michael P Reilly; Gowthami Arepally; John W Weisel; Chandrasekaran Nagaswami; Douglas B Cines; Bruce S Sachais Journal: Blood Date: 2004-08-10 Impact factor: 22.113
Authors: Gang Zheng; Michael B Streiff; Clifford M Takemoto; Jennifer Bynum; Elise Gelwan; Jayesh Jani; Danielle Judge; Thomas S Kickler Journal: Clin Appl Thromb Hemost Date: 2017-08-04 Impact factor: 2.389
Authors: Anand Padmanabhan; Curtis G Jones; Shannon M Pechauer; Brian R Curtis; Daniel W Bougie; Mehraboon S Irani; Barbara J Bryant; Jack B Alperin; Thomas G Deloughery; Kevin P Mulvey; Binod Dhakal; Renren Wen; Demin Wang; Richard H Aster Journal: Chest Date: 2017-04-17 Impact factor: 9.410
Authors: Yuhang Zhou; Shaji Abraham; Pierrette Andre; Leonard C Edelstein; Chad A Shaw; Carol A Dangelmaier; Alexander Y Tsygankov; Satya P Kunapuli; Paul F Bray; Steven E McKenzie Journal: Blood Date: 2015-10-29 Impact factor: 22.113
Authors: Curtis G Jones; Shannon M Pechauer; Brian R Curtis; Daniel W Bougie; Richard H Aster; Anand Padmanabhan Journal: Blood Date: 2017-12-19 Impact factor: 22.113
Authors: Curtis G Jones; Shannon M Pechauer; Brian R Curtis; Daniel W Bougie; Mehraboon S Irani; Binod Dhakal; Brenda Pierce; Richard H Aster; Anand Padmanabhan Journal: Chest Date: 2017-10 Impact factor: 9.410